RespireRx Pharmaceuticals Inc (fka RSPI)

[atheroprevent]

nothing positive that I can recall re AD... perhaps some implied administrative or IRB issues because of a mention of possibly having to look at some new sites (don't know whether he was ref to future or present studies), but Stoll's focus was clearly all RD. There are better ears on this board than mine.